vs

Side-by-side financial comparison of ANAVEX LIFE SCIENCES CORP. (AVXL) and Palladyne AI Corp. (PDYN). Click either name above to swap in a different company.

Palladyne AI Corp. is the larger business by last-quarter revenue ($1.7M vs $1.1M, roughly 1.5× ANAVEX LIFE SCIENCES CORP.). Palladyne AI Corp. runs the higher net margin — -89.9% vs -526.5%, a 436.6% gap on every dollar of revenue. On growth, Palladyne AI Corp. posted the faster year-over-year revenue change (118.3% vs -22.6%). Over the past eight quarters, ANAVEX LIFE SCIENCES CORP.'s revenue compounded faster (-21.6% CAGR vs -30.5%).

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical firm focused on developing novel small molecule therapeutics for neurodegenerative and neurodevelopmental disorders such as Alzheimer’s disease, Rett syndrome and Parkinson’s disease. It operates mainly across North America and European markets, targeting patients with high unmet medical needs.

Palladyne AI Corp. is an American company known for most of its existence primarily as a developer of robots. Palladyne was founded in 1983 as Sarcos Research Corporation. In 2023, Sarcos shifted its business focus to the development of artificial intelligence (AI) software for robotic applications, discontinuing its hardware operations. In March 2024, the company changed its name to Palladyne AI.

AVXL vs PDYN — Head-to-Head

Bigger by revenue
PDYN
PDYN
1.5× larger
PDYN
$1.7M
$1.1M
AVXL
Growing faster (revenue YoY)
PDYN
PDYN
+140.9% gap
PDYN
118.3%
-22.6%
AVXL
Higher net margin
PDYN
PDYN
436.6% more per $
PDYN
-89.9%
-526.5%
AVXL
Faster 2-yr revenue CAGR
AVXL
AVXL
Annualised
AVXL
-21.6%
-30.5%
PDYN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AVXL
AVXL
PDYN
PDYN
Revenue
$1.1M
$1.7M
Net Profit
$-5.7M
$-1.5M
Gross Margin
15.6%
Operating Margin
-628.5%
-560.7%
Net Margin
-526.5%
-89.9%
Revenue YoY
-22.6%
118.3%
Net Profit YoY
53.1%
97.2%
EPS (diluted)
$-0.06
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVXL
AVXL
PDYN
PDYN
Q4 25
$1.1M
$1.7M
Q3 25
$999.0K
$860.0K
Q2 25
$1.1M
$1.0M
Q1 25
$1.2M
$1.7M
Q4 24
$1.4M
$761.0K
Q3 24
$1.8M
$871.0K
Q2 24
$1.8M
$2.7M
Q1 24
$1.8M
$3.4M
Net Profit
AVXL
AVXL
PDYN
PDYN
Q4 25
$-5.7M
$-1.5M
Q3 25
$-9.8M
$-3.7M
Q2 25
$-13.2M
$-7.5M
Q1 25
$-11.2M
$22.8M
Q4 24
$-12.1M
Q3 24
$-11.6M
$-7.1M
Q2 24
$-12.2M
$-5.3M
Q1 24
$-10.5M
$-7.2M
Gross Margin
AVXL
AVXL
PDYN
PDYN
Q4 25
15.6%
Q3 25
46.4%
Q2 25
53.3%
Q1 25
79.4%
Q4 24
27.2%
Q3 24
45.0%
Q2 24
79.0%
Q1 24
45.2%
Operating Margin
AVXL
AVXL
PDYN
PDYN
Q4 25
-628.5%
-560.7%
Q3 25
-1085.5%
-937.8%
Q2 25
-1345.0%
-797.4%
Q1 25
-1034.1%
-405.3%
Q4 24
-975.0%
Q3 24
-810.9%
-838.0%
Q2 24
-813.1%
-213.3%
Q1 24
-718.9%
-213.7%
Net Margin
AVXL
AVXL
PDYN
PDYN
Q4 25
-526.5%
-89.9%
Q3 25
-983.7%
-434.9%
Q2 25
-1231.9%
-737.6%
Q1 25
-925.3%
1330.9%
Q4 24
-868.8%
Q3 24
-660.2%
-814.7%
Q2 24
-680.1%
-196.2%
Q1 24
-600.6%
-210.1%
EPS (diluted)
AVXL
AVXL
PDYN
PDYN
Q4 25
$-0.06
$-0.02
Q3 25
$-0.11
$-0.09
Q2 25
$-0.16
$-0.20
Q1 25
$-0.13
$0.55
Q4 24
$-0.14
Q3 24
$-0.14
$-0.27
Q2 24
$-0.14
$-0.20
Q1 24
$-0.13
$-0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVXL
AVXL
PDYN
PDYN
Cash + ST InvestmentsLiquidity on hand
$131.7M
$47.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$126.6M
$74.7M
Total Assets
$133.0M
$95.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVXL
AVXL
PDYN
PDYN
Q4 25
$131.7M
$47.1M
Q3 25
$102.6M
$57.1M
Q2 25
$101.2M
$62.7M
Q1 25
$115.8M
$46.6M
Q4 24
$120.8M
$40.1M
Q3 24
$132.2M
$21.3M
Q2 24
$138.8M
$25.8M
Q1 24
$139.4M
$31.8M
Stockholders' Equity
AVXL
AVXL
PDYN
PDYN
Q4 25
$126.6M
$74.7M
Q3 25
$94.9M
$51.8M
Q2 25
$91.0M
$53.8M
Q1 25
$99.8M
$28.3M
Q4 24
$110.9M
$-9.5M
Q3 24
$120.3M
$23.4M
Q2 24
$129.8M
$29.8M
Q1 24
$135.0M
$34.2M
Total Assets
AVXL
AVXL
PDYN
PDYN
Q4 25
$133.0M
$95.7M
Q3 25
$103.8M
$72.9M
Q2 25
$102.4M
$78.3M
Q1 25
$117.1M
$63.3M
Q4 24
$124.0M
$56.3M
Q3 24
$135.6M
$38.7M
Q2 24
$141.5M
$45.1M
Q1 24
$144.5M
$50.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVXL
AVXL
PDYN
PDYN
Operating Cash FlowLast quarter
$-7.2M
$-8.5M
Free Cash FlowOCF − Capex
$-8.7M
FCF MarginFCF / Revenue
-526.2%
Capex IntensityCapex / Revenue
14.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVXL
AVXL
PDYN
PDYN
Q4 25
$-7.2M
$-8.5M
Q3 25
$-8.6M
$-6.3M
Q2 25
$-12.5M
$-5.3M
Q1 25
$-5.9M
$-7.5M
Q4 24
$-12.1M
$-22.6M
Q3 24
$-6.7M
$-4.5M
Q2 24
$-5.2M
$-5.8M
Q1 24
$-11.7M
$-7.2M
Free Cash Flow
AVXL
AVXL
PDYN
PDYN
Q4 25
$-8.7M
Q3 25
$-6.7M
Q2 25
Q1 25
$-7.6M
Q4 24
$-22.9M
Q3 24
$-4.5M
Q2 24
$-5.9M
Q1 24
$-7.3M
FCF Margin
AVXL
AVXL
PDYN
PDYN
Q4 25
-526.2%
Q3 25
-776.0%
Q2 25
Q1 25
-445.0%
Q4 24
-3008.1%
Q3 24
-517.8%
Q2 24
-218.9%
Q1 24
-212.1%
Capex Intensity
AVXL
AVXL
PDYN
PDYN
Q4 25
14.2%
Q3 25
44.7%
Q2 25
0.0%
Q1 25
5.4%
Q4 24
34.8%
Q3 24
1.4%
Q2 24
5.3%
Q1 24
1.8%
Cash Conversion
AVXL
AVXL
PDYN
PDYN
Q4 25
Q3 25
Q2 25
Q1 25
-0.33×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons